Welcome to our dedicated page for OnKure Therapeutics SEC filings (Ticker: OKUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech 10-K packed with clinical jargon or tracing insider trades before a data readout can feel like lab work itself. OnKure Therapeutics’ filings are especially dense because every page details mutant-selective PI3K research, cash runway projections, and trial risk factors. If you have wondered, “How do I navigate OnKure Therapeutics SEC filings explained simply?” or need a quick view of OnKure Therapeutics insider trading Form 4 transactions, you’re in the right place.
Stock Titan’s platform converts raw disclosures into clarity. Our AI-powered summaries highlight where the 10-K discusses pending OKI-219 trial milestones, flag liquidity sections, and translate complex notes into plain English—understanding OnKure Therapeutics SEC documents with AI really is that direct. Real-time feeds push OnKure Therapeutics Form 4 insider transactions real-time straight to your dashboard, while side-by-side comparisons make every OnKure Therapeutics quarterly earnings report 10-Q filing easier to track. Key use cases include:
- Spot executive sentiment through OnKure Therapeutics executive stock transactions Form 4
- Measure R&D burn rate across quarters via AI-annotated 10-Qs
- Receive instant alerts when an OnKure Therapeutics 8-K material events explained filing hits EDGAR
Whether you’re preparing a discounted cash-flow model or just asking, “Where’s the OnKure Therapeutics annual report 10-K simplified?”, our tools surface what matters: pipeline timelines, dilution risks, and partnership revenue clauses. Detailed tag-along notes demystify the OnKure Therapeutics proxy statement executive compensation language and link it to performance targets. Save hours of manual review—our AI turns each OnKure Therapeutics earnings report filing analysis into clear next steps so you can focus on investment decisions, not document digging.
Nicholas A. Saccomano, President and CEO and a director of OnKure Therapeutics, Inc. (OKUR), reported a routine transaction on 09/22/2025 in which 88 shares of Class A Common Stock were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). The sale executed in multiple trades at prices ranging from $2.60 to $2.645, producing a weighted average sale price of $2.6235. Following the transaction, the reporting person beneficially owned 3,506 shares (certain of which remain as RSUs subject to vesting conditions). The Form 4 was signed by proxy on 09/24/2025.
OnKure Therapeutics CFO Jason A. Leverone reported a routine disposition of Class A common stock to cover tax withholding tied to RSU vesting. On 09/22/2025 the reporting person sold 303 shares at a weighted average price of $2.6235, leaving beneficial ownership of 12,603 shares. The filing explains the sale was automatic under the companys 2023 RSU Equity Incentive Plan and that RSUs represent contingent rights to receive one share upon vesting. The Form 4 was submitted under power of attorney on 09/24/2025.
FAQ
What is the current stock price of OnKure Therapeutics (OKUR)?
What is the market cap of OnKure Therapeutics (OKUR)?
